IMS Health announced the acquisition of Semantelli Corporation, a Bridgewater, N.J.-based social media analytics company, to extend its marketing and consumer engagement capabilities for healthcare organizations around the world. Semantelli offers clients a robust set of cloud-based tools that automate the collection of healthcare-specific social media content, providing real-time monitoring for reputation and opportunity management and delivering extensive insights into consumer and physician behavior and sentiments.
Semantelli’s proprietary technologies enable organizations to access, navigate and analyze both structured and unstructured data from thousands of online resources, including popular social networks and other social media platforms. The company’s global web 3.0 platform supports more than 50 languages and leverages a comprehensive set of medical taxonomies and algorithms, as well as state-of-the-art Named Entity Recognition, Natural Language Processing and Machine Learning, to detect trends in disease areas and treatments. In addition, insights on healthcare professionals can be integrated into traditional customer relationship management (CRM) systems, making it easier for clients to get greater value from their commercial data.
Semantelli’s flagship software “AE Tracker” helps life sciences and healthcare companies manage Adverse Events and other compliance risks in social media and mobile apps 24/7. The company also offers a Pharma specific social listening platform can help uncover patient journeys and unmet patient/HCP needs that can augment your traditional market research. The startup’s 17 employees will move into an IMS office in Parsippany, NJ.
“Social media has become an integral part of the healthcare experience, and navigating this channel effectively to unlock the right information for making decisions is critical. The combination of Semantelli’s technology and IMS’s healthcare data and privacy management expertise will fuel ongoing innovation in a responsible manner, enabling our clients to identify vital trends and take actions on real-world insights in real time,” says Stefan Linn, senior vice president, Strategy & Global Pharmaceutical Solutions, IMS
For more details see their official press release.
